Top ▲


Click here for help

Target id: 1361

Nomenclature: CYP17A1

Family: CYP11, CYP17, CYP19, CYP20 and CYP21 families

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 508 10q24.32 CYP17A1 cytochrome P450 family 17 subfamily A member 1
Mouse - 507 19 38.97 cM Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1
Rat - 507 1q54 Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1
Previous and Unofficial Names Click here for help
Steroid 17-α-hydroxylase/17,20 lyase | cytochrome P450 17A1 | steroid 17-alpha hydroxylase | cytochrome P450, family 17, subfamily a, polypeptide 1 | cytochrome P450, family 17, subfamily A, polypeptide 1 | cytochrome P450
Database Links Click here for help
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
Enzyme Reaction Click here for help
EC Number:
EC Number:

Download all structure-activity data for this target as a CSV file go icon to follow link

Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
levoketoconazole Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibition 7.4 pKi 3
pKi 7.4 (Ki 3.8x10-8 M) [3]
abiraterone Small molecule or natural product Primary target of this compound Ligand has a PDB structure Hs Inhibition 7.1 – 7.3 pIC50 1,4
pIC50 7.1 – 7.3 [1,4]
YXG-158 Small molecule or natural product Hs Inhibition 7.0 pIC50 5
pIC50 7.0 (IC50 1x10-7 M) [5]
galeterone Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 6.5 pIC50 2
pIC50 6.5 (IC50 3x10-7 M) [2]
Immuno Process Associations
Immuno Process:  Cytokine production & signalling
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  46,XY disorder of sex development due to isolated 17, 20 lyase deficiency
Synonyms: 46 XY gonadal dysgenesis [Disease Ontology: DOID:14448]
Disease Ontology: DOID:14448
OMIM: 614279
Orphanet: ORPHA90796
Disease:  Congenital adrenal hyperplasia due to 17-alpha-hydroxylase deficiency
Synonyms: Congenital adrenal hyperplasia [Disease Ontology: DOID:12255]
Disease Ontology: DOID:12255
OMIM: 202110
Orphanet: ORPHA90793


Show »

1. Haidar S, Ehmer PB, Barassin S, Batzl-Hartmann C, Hartmann RW. (2003) Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol, 84 (5): 555-62. [PMID:12767280]

2. Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman Jr D, Farquhar R, Guo Z, Qiu Y et al.. (2005) Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem, 48 (8): 2972-84. [PMID:15828836]

3. Njar VC, Kato K, Nnane IP, Grigoryev DN, Long BJ, Brodie AM. (1998) Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer. J Med Chem, 41 (6): 902-12. [PMID:9526564]

4. Potter GA, Barrie SE, Jarman M, Rowlands MG. (1995) Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem, 38 (13): 2463-71. [PMID:7608911]

5. Wang A, Luo X, Meng X, Lu Z, Chen K, Yang Y. (2023) Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer. J Med Chem, 66 (14): 9972-9991. [PMID:37458396]

How to cite this page